X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Divis Laboratories with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs MYLAN (US) - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   MYLAN
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
MYLAN
Dec-14
DIVIS LABORATORIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,1424,249-   
Low Rs5332,995-   
Sales per share (Unadj.) Rs146.61,454.8-  
Earnings per share (Unadj.) Rs33.0175.2-  
Cash flow per share (Unadj.) Rs38.4282.1-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs222.8723.2-  
Shares outstanding (eoy) m265.47378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.72.5 229.5%   
Avg P/E ratio x25.320.7 122.7%  
P/CF ratio (eoy) x21.812.8 169.8%  
Price / Book Value ratio x3.85.0 75.0%  
Dividend payout %30.30-   
Avg Mkt Cap Rs m222,3181,370,471 16.2%   
No. of employees `00010.825.0 43.0%   
Total wages/salary Rs m4,5610-   
Avg. sales/employee Rs Th3,616.022,017.4 16.4%   
Avg. wages/employee Rs Th423.80-   
Avg. net profit/employee Rs Th814.92,652.4 30.7%   
INCOME DATA
Net Sales Rs m38,915550,436 7.1%  
Other income Rs m1,134-3,209 -35.4%   
Total revenues Rs m40,049547,228 7.3%   
Gross profit Rs m12,617136,896 9.2%  
Depreciation Rs m1,42540,427 3.5%   
Interest Rs m1323,743 0.1%   
Profit before tax Rs m12,31369,518 17.7%   
Minority Interest Rs m0-285 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,5432,923 121.2%   
Profit after tax Rs m8,77066,309 13.2%  
Gross profit margin %32.424.9 130.4%  
Effective tax rate %28.84.2 684.3%   
Net profit margin %22.512.0 187.1%  
BALANCE SHEET DATA
Current assets Rs m45,351483,906 9.4%   
Current liabilities Rs m6,507378,318 1.7%   
Net working cap to sales %99.819.2 520.4%  
Current ratio x7.01.3 544.9%  
Inventory Days Days12778 162.3%  
Debtors Days Days95107 88.7%  
Net fixed assets Rs m21,160127,342 16.6%   
Share capital Rs m53119,465 2.7%   
"Free" reserves Rs m58,6250-   
Net worth Rs m59,156273,621 21.6%   
Long term debt Rs m0408,763 0.0%   
Total assets Rs m67,8321,102,120 6.2%  
Interest coverage x926.83.9 23,595.4%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.60.5 114.9%   
Return on assets %12.98.2 158.5%  
Return on equity %14.824.2 61.2%  
Return on capital %20.813.6 152.9%  
Exports to sales %00-   
Imports to sales %21.80-   
Net fx Rs m23,3170-   
CASH FLOW
From Operations Rs m7,75972,355 10.7%  
From Investments Rs m-4,783-57,061 8.4%  
From Financial Activity Rs m-3,142-19,066 16.5%  
Net Cashflow Rs m-166-3,772 4.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.3 Rs / USD

Compare DIVIS LABORATORIES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DIVIS LABORATORIES With: VENUS REMEDIES  DR. REDDYS LAB  PIRAMAL ENTERPRISES  SUVEN LIFE  ALKEM LABORATORIES  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 21, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - MERCK LTD COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS